Hillsdale Investment Management Inc. Buys Shares of 320,272 Niagen Bioscience, Inc. $NAGE

Hillsdale Investment Management Inc. purchased a new stake in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 320,272 shares of the company’s stock, valued at approximately $2,988,000. Hillsdale Investment Management Inc. owned approximately 0.40% of Niagen Bioscience as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of NAGE. Financial Consulate Inc. acquired a new stake in Niagen Bioscience during the third quarter valued at $33,000. State of Alaska Department of Revenue purchased a new stake in shares of Niagen Bioscience during the 3rd quarter worth about $44,000. North Star Investment Management Corp. purchased a new stake in shares of Niagen Bioscience during the 3rd quarter worth about $47,000. AlphaQuest LLC acquired a new stake in shares of Niagen Bioscience during the 3rd quarter valued at about $75,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Niagen Bioscience in the 3rd quarter valued at approximately $107,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Canaccord Genuity Group dropped their price objective on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Niagen Bioscience has a consensus rating of “Moderate Buy” and an average price target of $14.28.

Niagen Bioscience Stock Performance

Shares of NASDAQ:NAGE opened at $4.86 on Monday. The stock’s 50-day moving average is $6.03 and its 200-day moving average is $7.44. The company has a market cap of $387.88 million, a P/E ratio of 20.25 and a beta of 2.35. Niagen Bioscience, Inc. has a 52-week low of $4.78 and a 52-week high of $14.69.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.